Allergan Aesthetics (AbbVie) said the European Commission approved Boey for the temporary improvement of moderate-to-severe glabellar (frown) lines in adults. This is a positive regulatory milestone, supporting continued product availability/uptake in Europe, though the article provides no financial guidance or sales impact estimate.
Allergan Aesthetics (AbbVie) said the European Commission approved Boey for the temporary improvement of moderate-to-severe glabellar (frown) lines in adults. This is a positive regulatory milestone, supporting continued product availability/uptake in Europe, though the article provides no financial guidance or sales impact estimate.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
